R-Pharm Group and Beijing Health Guard signed a letter of intent on HPV vaccines

September 5

The two companies aim to develop and commercialize a nonavalent HPV vaccine in Russia to help prevent HPV infections and associated diseases, especially cervical cancer

September 5, 2019 - At the East Economic Forum 2019 held in Vladivostok, Russia, R-Pharm Group, a leader of the Russian healthcare market, and Beijing Health Guard Biotechnology, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel protein-based biologics against infectious diseases, signed an agreement of intent to collaborate on a nonavalent HPV (human papillomavirus) project. The vaccine developed by Beijing Health Guard includes as antigens virus-like particles of nine high-risk HPV types that combined are responsible for ~90% of cervical cancer cases worldwide. Both parties articulated their deep interest in a development and commercialization collaboration for the nonavalent HPV vaccine to help eliminate human papillomavirus infections and associated diseases in Russian Federation. The letter of intent was signed by chairman of the board of R-Pharm Group, Mr. Alexey Repik, and chairman of the board of Beijing Health Guard, Mr. Chunli Hao.

”It is of the utmost importance to make innovative HPV vaccines available to all Russian citizens. This virus provokes genetic mutations leading to cervical cancer, one of the most widely spread oncological diseases in Russia. I strongly believe, that the high-tech product of our partner will help us improve the healthcare system and defeat this dangerous virus once and for all”, said Mr. Alexey Repik.

“Beijing Health Guard remains dedicated to the development of innovative protein-based biologics, specifically vaccines, for the protection against infectious diseases in China and around the globe. We are excited to partner with R-Pharm Group on the further development and potential commercialization of our nonavalent HPV vaccine in Russia, where HPV infections and diseases it causes, in particular cervical cancer, continue to pose a significant public health burden”, stated Mr. Hao. “Collaboration between Beijing Health Guard and R-Pharm Group on the HPV vaccine project amounts to an incredible synergy of technology and market, which will allow us to bring our quality yet cost-effective vaccine to Russian citizens in need, thereby contributing to the Russian public health. We also believe this will only be a start to a potentially more extensive collaboration in the future between the parties that in turn will drive further exchange and cooperation between Chinese and Russian pharmaceutical industries, enriching the strategic partnership between China and Russia.”

About HPV and HPV infections

HPV is a group of more than 200 related viruses, some of which are spread through vaginal, anal, or oral sex. Sexually transmitted HPV types fall into two groups, low risk and high risk. Nearly all sexually active people are infected with HPV almost immediately after they become sexually active. Most HPV infections are self-limiting, while high-risk HPV infections that persist can cause cancers in anatomical sites like cervix, anus, vagina and vulva. HPV vaccines can prevent infection with disease-causing HPV types, and thus protect against many HPV-related cancers and cases of genital warts.

About cervical cancer

Cervical cancer is the second most common gynecological malignancy worldwide, and is diagnosed among ~540,000 women annually, with over 50% of the cohort ending up dead, representing a major global public health concern. Virtually all cervical cancer cases are caused by persistent high risk HPV infection. The Russian healthcare system registered more than 17,500 cases of cervical cancer in 2018. This oncological disease is considered to be the second most common cancer in women under the age of 45 in Russia. According to the data collected by P. A. Hertsen Moscow Oncology Research Center, the number of cervical cancer patients registered in Russia has increased by 30% over the past 10 years.

About the nonavalent HPV vaccine

The production of Beijing Health Guard’s nonavalent HPV vaccine employs patented strategies to express L1 proteins of vaccine HPV types in E. coli as soluble pentamers at low cost and with high efficiency. The derived L1 pentamers can be purified and assemble into highly homogeneous VLPs in vitro without a disassembly-reassembly process. Theoretically, the nonavalent HPV vaccine developed by Beijing Health Guard would afford protection against ~90% of cervical cancer cases and more than 90% of genital warts. Currently, Phase I study has been initiated for the nonavalent HPV vaccine in China.

About Beijing Health Guard

Beijing Health Guard Biotechnology Inc., a clinical-stage biopharmaceutical company, is committed to the discovery, development and commercialization of innovative biologics for the prevention of infectious diseases. Beijing Health Guard’s structure-guided vaccine design platform has generated two investigational HPV vaccines, i.e. a trivalent and a nonavalent HPV vaccine, both of which are currently in clinical trials (Phase II concluded for the trivalent, Phase I underway for the nonavalent). Other ongoing research efforts include the development of a 15-valent HPV vaccine, a quadrivalent HFMD vaccine, a polyvalent norovirus vaccine, and a therapeutic HPV vaccine. Beijing Health Guard is certified by Beijing Municipal Science & Technology Commission as a National High-Tech Enterprise.

Other company news

September 6, 2019 — Targeting increased access to advanced cancer care for patients in Russia, Fabrika RTT (part of R-Pharm Group) and...
read more...
September 5
June 29, 2019 Canon Medical Systems Corporation (Headquarters: Otawara, Tochigi Prefecture, Japan; President and CEO: Toshio Takiguchi) has...
read more...
July 1
06 November 2018 – R-Pharm Group and the Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard:...
read more...
November 6